Methode Electronics: 10% Sales Growth Wasn't the Problem — Flat Guidance Was

Methode Electronics sold off on the news that its fiscal first-quarter sales rose 10%. On the surface that reads like a paradox. It isn't. Look at the numbers the report actually carried and the stock's move makes sense.

The company, a $580 million maker of power distribution, sensors, lighting, and user-interface components for autos, trucks, and data centers, reported net sales of $265.4 million for the quarter ended August 1, up 10.4% from a year earlier and comfortably ahead of the $231.6 million analysts had modeled. It still lost $11.4 million, or $0.32 a diluted share, a wider loss than the $10.3 million a year earlier, and adjusted EBITDA fell to $13.7 million from $15.7 million. The shares dropped about 23% after the close and were down roughly 10% the next day.

That gap between a beat on the top line and a selloff is the whole story. Sales growth is not profit growth, and Methode is still a company in the middle of losing money on an adjusted basis. The market didn't sell the quarter; it sold the gap between where the stock was priced and where the bottom line actually stands.

A discount that comes with a reason

By the factor stack most screens look at, Methode looks absurdly cheap. It trades at roughly 0.9 times book value — below what shareholders have in it — and at 0.56 times sales. Compare that with Amphenol, the sector's blue-chip comparator, at about 12.7 times book and 6.8 times sales, or TE Connectivity at 4.4 times book and 3.1 times sales.

But cheapness is never absolute. Methode carries those discounts for the same reason its peers don't: Amphenol and TE make fat margins and cash, while Methode loses money, with negative return on equity and return on invested capital on a trailing basis. A below-book price on a loss-making turnaround is a discount on the repair, not on earnings. It only becomes a value if the repair completes.

The underappreciated part of the story is that the repair is real on the operating side. Industrial segment sales jumped 27% to $156.8 million, driven by data centers and heavy-truck and construction lighting, and Industrial is now more than half of total revenue. Gross profit rose to $47.7 million from $43.5 million. The growth engine is functioning.

Expectations moved faster than the income statement

What got repriced wasn't the quarter — it was the year. This is a stock that had already climbed roughly 148% year to date and 217% over four months, from a 52-week low of $4.88 to a high of $20.38 right before earnings. The rally was the market pricing in not just a sales recovery but a fast path back to profit on the data-center theme.

That is why management's guidance mattered more than the quarter. Methode affirmed, rather than raised, its full-year outlook of $1.025 billion to $1.075 billion in net sales. Against fiscal 2026's roughly $1.0 billion, the midpoint implies only about 5% growth for the year — a deceleration from the 10.4% first-quarter pace. For a stock that tripled, "no change" reads as disappointment, regardless of the quarterly beat.

The balance sheet adds the finishing constraint. Methode carried net debt of about $194 million on a market cap of $580 million, and free cash flow is still negative on a trailing basis. It repaid $10.1 million of debt in the quarter and extended its revolver to 2028, so the liquidity is workable — but a turnaround this levered has to start throwing off cash, not just revenue.

What the factor verdict turns on

I run Methode against this framework the same way I run every name: sector-relative comparison first, a five-factor read across valuation, growth, profitability, safety, and momentum, and an aggregate signal only as a cross-check. On that stack, growth is real and accelerating in the segment that matters, valuation is superficially cheap but earned, and safety is improving but not yet self-funding. The deciding grades are the two Methode hasn't delivered: profitability, still negative, and momentum, which has cooled — the stock fell back to right around its 50-day average with the RSI near neutral after the run. AInvest's aggregate signal labels the shares a Buy, which is consistent with a transformation that is working. But it does not tell you when.

The mistake would be to read this article's opening — sales up, stock down — as a signal that the 10% growth was somehow fake. It wasn't. The selloff is the market waking up to timing: the revenue inflection is priced and delivered; the profit inflection is not. For an investor deciding whether this name belongs in a growth sleeve or a watch list, the number to track is not next quarter's sales. It is the quarter when the net loss flips to a profit. That is the moment the discount stops being a bet on a turnaround and starts becoming a value.